Pregabalin Capsule 50 mg
Pregabalin 50mg
Hard capsule · Prescription medication
Shinil Pharmaceutical Co., Ltd.
MFDS item code 201906160 · Approved 2019.08.29
This product's status changed to Expired on 2024.08.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used effectively to alleviate peripheral and central neuropathic pain in adults. It also assists in the adjunctive treatment of partial seizures in patients with epilepsy, helping to reduce the frequency of seizures. Additionally, it is used to alleviate pain and discomfort caused by fibromyalgia. This medication is widely used for neurological disorders and pain relief, contributing to an improved quality of life for patients.
This medication is administered orally, with or without food, in two divided doses of the total daily dose of pregabalin. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), which may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalinᵃ 150-600, BID or TID ≥30-<60: Total daily dose of pregabalinᵃ 75-300, BID or TID ≥15-<30: Total daily dose of pregabalinᵃ 25-50-150, BID or TID <15: Total daily dose of pregabalinᵃ 25-75, QD or BID Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: As there are insufficient safety and efficacy data, use is not recommended. Adolescent patients aged 12-17 years: As there are insufficient safety and efficacy data, use is not recommended.
This medication may increase the risk of suicidal ideation or behavior; therefore, patients should immediately inform their healthcare provider of any changes in mood or behavior during treatment. Patients with hypersensitivity to this drug or a genetic problem of lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may necessitate adjustments in blood sugar control medications. If symptoms of angioedema occur, the medication should be discontinued immediately, and consultation with a healthcare provider is necessary. Elderly patients should be cautious due to the higher risk of falls from dizziness or drowsiness. Temporary visual blurring or changes in vision may occur; if symptoms are severe, discontinuation of the medication should be considered. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, it should be tapered off gradually under the guidance of a healthcare provider. Patients with a history of drug abuse may be at a higher risk of misuse of this medication and should use it cautiously. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should be cautious as this medication may worsen symptoms of heart failure during administration. When used in conjunction with other medications that have central nervous system depressant effects, the risk of drowsiness or respiratory depression may increase. During early pregnancy, there is a risk of birth defects; thus, women who are pregnant or planning to become pregnant must consult with a healthcare provider. This medication may pass into breast milk, so it is recommended to discontinue breastfeeding or the medication while nursing. Patients should avoid hazardous activities such as driving or operating machinery until dizziness or drowsiness has resolved after taking this medication. In cases of overdose, symptoms such as altered consciousness, drowsiness, and confusion may occur, and immediate emergency treatment is necessary. Keep out of reach of children and ensure it is not transferred to other containers.
Suicidal thoughts, suicidal behavior, depression, abnormal mood and behavior changes, angioedema, facial swelling, periorbital swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, pain, sweating, misuse and abuse, dependence, hypoglycemia, increased appetite, decreased appetite, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, dysesthesia, restlessness, agitation, mood disturbances, emotional lability, hallucinations, abnormal dreams, increased libido, panic attacks, impulse control issues, flat affect, ataxia, abnormal motor coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory disturbances, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, speech disorders, myoclonic jerks, decreased reflexes, abnormal movement, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremor, syncope, confusion, motor retardation, olfactory disturbances, taste loss, writing difficulties, diplopia, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, bradycardia, supraventricular tachycardia, atrial arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling drunk, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase in blood, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium in blood, weight loss, increased creatinine in blood, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, agitation, seizures, shock, anaphylaxis-like symptoms, epidermal mucosal syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to keep the storage temperature between 15 and 30 degrees Celsius.
A hard capsule with purple upper part and white lower part containing white powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 50mg
Hard capsule · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.